The Wall Street Journal Editorial Board is reporting on several key issues, including criticisms of the Food and Drug Administration and insights from newly released diaries. It said FDA staff are accused of manipulating reviews to block new therapies for late-stage melanoma and Duchenne muscular dystrophy. The Editorial Board also commented on the legacy of Senator Lindsey Graham, questioning who might succeed him as a proponent for freedom and U.S. interests internationally. It highlighted Johnson & Johnson's successful efforts against what it termed "junk lawsuits" related to talc. Additionally, the board noted that newly released diaries from Dr. Anthony Fauci present a different narrative than his public statements during the COVID-19 pandemic.
In commentary, Mark Zuckerberg argued that the future of artificial intelligence should be accessible to everyone, stating that centralized power hinders human potential. Jay Bhattacharya discussed how the National Institutes of Health aims to end dangerous gain-of-function research while fostering life sciences. Ari Emanuel suggested that a Paramount-Warner merger could benefit Hollywood, criticizing California's attorney general for ignoring competition realities.
Columnists also weighed in, with Jason L. Riley asserting that public charter schools are crucial for closing the academic achievement gap among minority and low-income students. Holman W. Jenkins, Jr. wrote about attorneys general using antitrust law against Donald Trump and MAGA. William A. Galston commented that Donald Trump has a valid point regarding the Smithsonian's American history museum becoming an instrument of "left-wing culture warriors."